+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 11 Actively Recruiting clinical trials

P

Actively Recruiting

This trial investigates MZE829 capsules in adults with proteinuric chronic kidney disease who also carry the APOL1 high risk genotype, specifically G1G1, G2G2, or G1G2 variants. The study aims to evaluate the safety, tolerability, and impact on albuminuria, a marker of kidney damage, in this population. It is an open-label Phase 2 trial, meaning all participants receive the study drug and results will help determine its effects and safety profile. Participants receive MZE829 capsules orally in a single-group design. The study includes two cohorts one with chronic kidney disease alongside diabetes, and another with chronic kidney disease without diabetes. The treatment and monitoring occur over a 12-week period, during which the study team assesses drug safety and effects on albuminuria levels. During the trial, participants will be monitored for adverse events and tolerability from baseline through week 12. Researchers will also measure changes in urine albumin-to-creatinine ratio UACR to evaluate kidney function. Blood samples will be taken to assess plasma drug concentrations. The total participation time is approximately 12 weeks, focusing on safety and biological effects of MZE829.

Age: 18Years - 68YearsAll GendersPhase 2
79 locations
S

Actively Recruiting

Researchers are studying osivelotor, an oral drug, in adults and adolescents with sickle cell disease SCD. This Phase 23 trial aims to evaluate the safety, tolerability, effectiveness, and how the body processes the drug. The study includes participants with specific SCD types and looks to find the best dose while also comparing the drug against a placebo over 48 weeks. A long-term extension will assess ongoing safety and blood response. The study has three parts. Part A tested safety and dose in adults to find the optimal dose. Part B compares osivelotor to placebo in adults and adolescents over 48 weeks, with adults receiving a loading dose of 300 mg daily for 7 days then 150 mg daily, while adolescent doses will be defined later. An open-label extension allows participants who completed Part B to take osivelotor for up to two years or until it becomes commercially available. Participants will undergo screening to confirm eligibility, including stable hemoglobin levels and SCD history. During the trial, participants receive study medication or placebo and attend regular visits for monitoring. Researchers will assess safety, blood characteristics, and vaso-occlusive crisis events. The study includes careful monitoring of adverse events and blood tests, with a total participation period that may last up to two years for those in the extension phase.

Age: 12Years +All GendersPhase 2Phase 3
80 locations
S

Actively Recruiting

This research aims to evaluate the effectiveness, safety, and tolerability of combining baxdrostat with dapagliflozin compared to dapagliflozin alone in people with chronic kidney disease CKD and high blood pressure. The goal is to reduce the risk of serious kidney problems, heart failure events, or cardiovascular death. This is a phase III, international, multicenter, randomized, double-blind, placebo-controlled, event-driven study focused on treatment outcomes. Participants who do not already use SGLT2 inhibitors will first undergo a 4-week dapagliflozin run-in period. After that, they will be randomly assigned to receive either baxdrostat plus dapagliflozin or placebo plus dapagliflozin. Baxdrostat dosing may start low and be increased if needed. Study visits will occur frequently early on at 2, 4, 8, 16, 34, and 52 weeks post-randomization, then approximately every 4 months. The study will end when a predetermined number of kidney or cardiovascular events occur. During the study, participants will have scheduled visits for assessments including kidney function, heart health, and safety monitoring. If they stop the study treatment early, they will continue on dapagliflozin alone and remain in the trial for follow-up visits. Researchers will measure outcomes such as sustained kidney function decline, kidney failure, heart failure events, cardiovascular death, and all-cause death over up to 37 months. Data collection continues until the study closes, with safety and tolerability closely observed throughout.

Age: 18Years +All GendersPhase 3
771 locations
P

Actively Recruiting

Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.

Age: 18Years +All GendersPhase 3
1452 locations
C

Actively Recruiting

Healthy Volunteer

Researchers are evaluating a new approach to prevent cardiovascular events in people at increased risk due to age and conditions like diabetes, prediabetes, or metabolic syndrome but who do not have symptoms of cardiovascular disease. The study compares a personalized care strategy based on the Cleerly Coronary Artery Disease CAD Staging System with the usual risk factor-based care. This approach aims to better identify and treat individuals with underlying atherosclerosis to reduce cardiovascular events. Participants are randomly assigned to one of two groups. The risk factor-based care group is managed by their usual healthcare providers, with oversight from a centralized cardiology team that monitors treatments and lab results without seeing coronary imaging results. The Cleerly stage-based care group receives personalized management from a remote cardiologist-led team using the Cleerly CAD Staging System, which includes coronary artery imaging, algorithm-driven medication adjustments, and education. Care is intensified if plaque worsens at 24 months. During the study, participants undergo assessments including coronary computed tomography angiography CCTA and lab tests. Researchers monitor cardiovascular events over an average of 3.5 years to compare the two care strategies. Medication use, lab values, and clinical outcomes related to cardiovascular and kidney health are tracked. The study includes electronic communication tools to support personalized care and aims to improve prevention through more precise disease staging and management.

Age: 55Years +All GendersPhase Not Applicable
125 locations
P

Actively Recruiting

Researchers are evaluating the safety, tolerability, and effects of ORX750 in adults with Narcolepsy Type 1 NT1, Narcolepsy Type 2 NT2, and Idiopathic Hypersomnia IH. These rare conditions cause excessive daytime sleepiness and affect daily activities such as school, work, and driving. The study aims to understand how ORX750, which mimics the brain protein orexin that helps maintain wakefulness, impacts sleepiness and other symptoms in these conditions. Participants will receive either ORX750 capsules or matching placebo capsules in a randomized, double-blind setup. The study assesses multiple groups those with NT1, NT2, and IH. The treatment and monitoring will occur over a period of up to 35 days, including evaluation of plasma drug levels and sleepiness measures. During the study, participants will undergo safety assessments including monitoring for adverse events, laboratory tests, vital signs, ECGs, and suicidal ideation screening up to day 35. Researchers will also measure sleepiness using the Maintenance of Wakefulness Test and the Epworth Sleepiness Scale. The total study duration for each participant is about five weeks, with careful observation of how the body processes ORX750 and its effects on daytime alertness.

Age: 18Years - 65YearsAll GendersPhase 2
37 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating an investigational mRNA seasonal flu vaccine compared to a licensed flu vaccine in adults aged 65 years and older. The study aims to assess the ability of the vaccines to prevent laboratory-confirmed influenza illness, monitor side effects, and measure immune responses during the flu season. This Phase 3 randomized, observer-blind trial is sponsored by GlaxoSmithKline and focuses on flu prevention in older adults. Participants will receive a single injection on Day 1 of either the investigational mRNA seasonal flu vaccine or a licensed, age-appropriate, season-adapted influenza vaccine. The study follows a parallel group design where participants are randomly assigned to one of these two vaccine groups. The follow-up period covers the entire influenza season to assess vaccine efficacy and safety. During the study, participants will be monitored for influenza-like illness confirmed by laboratory tests from Day 15 through the end of the influenza season. Safety assessments include tracking solicited local and systemic side effects from Day 1 to Day 7, unsolicited adverse events up to Day 28, and serious adverse events or special interest adverse events through at least 180 days of follow-up. Blood samples will be collected before dosing and on Day 29 to evaluate immune responses. Participants are followed for safety and efficacy throughout the flu season, with total involvement spanning several months.

Age: 65Years +All GendersPhase 3
163 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of crizanlizumab, a biological drug given at 5 mgkg, compared to a placebo in adolescents and adults aged 12 years and older who have Sickle Cell Disease and experience frequent vaso-occlusive crises VOCs. This phase III, multicenter, randomized, double-blind study includes patients who may or may not be receiving hydroxyurea or hydroxycarbamide therapy. The study aims to better understand how crizanlizumab impacts the rate and severity of VOCs in this population. Participants will be randomly assigned in a 21 ratio to receive either crizanlizumab or placebo, with both groups continuing standard care. The treatment is given as an intravenous infusion and the study allows patients to continue stable doses of hydroxyurea or hydroxycarbamide if they are already on these therapies. The randomization is stratified by hydroxyureahydroxycarbamide use and geographic region. The study treatment period lasts for one year, during which participants receive regular infusions and monitoring. During the trial, participants will be closely monitored with healthcare assessments to track the number of healthcare professional-managed VOCs, time to first VOC, and other important measures such as duration of VOCs, antibody development to the study drug, and changes in hemoglobin levels. Safety is closely evaluated through recording of adverse events over a two-year period. Participants will have regular visits for treatment and evaluation throughout the study, which is expected to last up to six years including follow-up and completion phases.

Age: 12Years - 100YearsAll GendersPhase 3
36 locations
E

Actively Recruiting

Researchers are evaluating depemokimab as a treatment for adults with moderate to severe chronic obstructive pulmonary disease COPD who have type 2 inflammation and uncontrolled symptoms. This Phase 3 study aims to assess the effectiveness and safety of depemokimab when added to standard care for these patients. The focus is on reducing COPD exacerbations and improving respiratory health. Participants will be randomly assigned to receive either depemokimab or a placebo along with their usual COPD treatments. Depemokimab is given as a sterile liquid formulation, and the study compares its effects against placebo over a period of up to 104 weeks. Both groups continue their optimized inhaler therapy during the trial. During the study, participants will undergo regular assessments including lung function tests, symptom questionnaires like the COPD assessment test CAT, and monitoring of exacerbations. Researchers will measure outcomes such as the rate of moderate or severe exacerbations annually and changes in respiratory symptoms. Safety and overall health are closely followed throughout the two-year treatment period.

Age: 40Years - 80YearsAll GendersPhase 3
281 locations
E

Actively Recruiting

Researchers are evaluating a medicine called survodutide in adults aged 18 and older who have confirmed non-alcoholic steatohepatitis NASH or metabolic-associated steatohepatitis MASH with cirrhosis, and a body mass index BMI of 27 kgm2 or higher, or 25 kgm2 for Asian participants. The study aims to find out if survodutide helps improve liver function and related health outcomes in these individuals. People with other chronic liver diseases or high alcohol intake are not eligible to participate. Participants are randomly assigned to one of two groups one group receives once-weekly injections of survodutide, and the other group receives a placebo injection that looks the same but contains no medicine. Both groups receive counseling to encourage dietary changes and regular exercise. The study is double-blinded, meaning neither participants nor doctors know which treatment is given. The trial lasts up to 4 and a half years, with visits either in person or via video calls scheduled every 2, 4, or 6 weeks for about 17 months, then every 3 months afterwards. Throughout the study, researchers monitor participants health, body weight, and any side effects. They use imaging methods to measure liver parameters and collect symptom questionnaires. The main outcome measured is the time until serious liver-related events occur, such as liver transplant or worsening liver function. Secondary outcomes include changes in liver fibrosis, body weight, blood sugar control, liver stiffness, and other health markers. This thorough monitoring helps compare the effects of survodutide to placebo over the long term.

Age: 18Years +All GendersPhase 3
447 locations

1-10 of 11

1